Table 1.
Patient characteristics
| Control | IAD | Hypophysitis | |
| Total number | 40 | 17 | 5 |
| Malignancy | |||
| MM | 24 | 9 | 4 |
| NSCLC | 10 | 5 | 0 |
| RCC | 4 | 2 | 1 |
| HN | 2 | 1 | 0 |
| Drugs | |||
| Ipi | 10 | 5 | 3 |
| Niv | 21 | 9 | 2 |
| Pem | 15 | 11 | 1 |
| Ipi+Niv | 5 | 1 | 2 |
| Ate | 0 | 1 | 0 |
| History of prior ICIs | 4 | 0 | 2 |
| Positive TPOAb or TgAb at baseline | 13 | 3 | 1 |
| Thyroid irAEs | 6 | 1 | 4 |
| Non-endocrine irAEs (≥G2) | 14 | 6 | 4 |
ACTH, adrenocorticotropic hormone; Ate, atezolizumab; HN, head and neck cancer; IAD, isolated ACTH deficiency; ICIs, immune checkpoint inhibitors; Ipi, ipilimumab; irAE, immune-related adverse event; MM, malignant melanoma; Niv, nivolumab; NSCLC, non-small cell lung carcinoma; Pem, pembrolizumab; RCC, renal cell carcinoma; TgAb, anti-thyroglobulin antibody; TPOAb, anti-thyroid peroxidase antibody.